Our technology

Bold Therapeutics' lead development candidate is BOLD-100, a novel first-in-class Cancer Resistance Pathway (CRP) inhibitor for the treatment of gastric, pancreatic and other cancers in combination with existing anti-cancer therapies. BOLD-100 has demonstrated synergy in established preclinical models in combination with a wide variety of anti-cancer therapies including traditional chemotherapies, tyrosine kinase inhibitors and checkpoint inhibitors.
 
BOLD-100 successfully completed a Phase 1 monotherapy study and was subsequently granted an Orphan Drug Designation (ODD) in pancreatic cancer. Additional ODDs are expected in the next 18 months. Bold Therapeutics expects to initiate one or more combination Phase 1/2 studies in mid 2019 at various sites in Canada and the United States.